Two longevity companies have bolstered their teams with the announcement of new board and executive appointments. Clinical stage longevity biotech Longeveron (NASDAQ: LGVN) announced the election of three new members to its board of directors, while cellular health supplements company MitoQ has appointed Dr Siobhan Mitchell as Chief Science and Technology Officer.
MitoQ is the developer of the cellular health molecule with the same name. By supporting mitochondria, the body’s primary energy source, MitoQ is designed to target cell stress and improve energy, increasing exercise recovery and promoting healthy aging.
“What led me to MitoQ was the incredible science behind its patented ingredient Mitoquinol Mesylate, and the exciting future for cellular health solutions,” said Mitchell. “MitoQ truly cares about gold standard science and has already shown to be hugely innovative as a supplement company.”
Mitchell, who relocated from the US to New Zealand’s MitoQ HQ for her new role, is a scientist with expertise in strategy, execution and launch of digital health programs and nutrition products with targeted health benefits and claims. In her role as CSO, Mitchell will drive the science strategy for MitoQ, ensuring the quality of all evidence relating to the company’s products. She will also spearhead partnerships with likeminded companies and universities.
“Siobhan is a fantastic addition to our team. She brings a depth of expertise and experience which will help take MitoQ to the next level,” said Mahara Inglis, CEO of MitoQ. “But more importantly – help everyone to understand the foundational role that cells play in their overall health and wellbeing.”
Longeveron, which develops cellular therapies for life-threatening and chronic aging-related conditions, said that Wa’el Hashad, Khoso Baluch, and Jeffrey Pfeffer were elected as board directors at the company’s recent Annual Meeting of Stockholders.
Wa’el Hashad is the current CEO of Longeveron. Khoso Baluch is the former CEO of CorMedix, a publicly traded pharmaceutical company, and has more 36 years’ experience in the biopharmaceutical industry. Jeffrey Pfeffer is the Thomas D. Dee II Professor of Organizational Behavior at the Graduate School of Business, Stanford University, where he has taught since 1979.
“We are very honored to welcome such prominent and experienced new members to our Board and look forward to their tremendous expertise, diverse experience, and counsel as we continue to advance our regenerative medicine toward critical milestones,” said Dr Joshua M Hare, Chairman of Longeveron.
“These individuals bring a wealth of critical experience to help Longeveron’s growth, and under Mr Hashad’s leadership as our new Chief Executive Officer, we are even more excited about the potential of Lomecel-B, our lead investigational product, and look forward to accelerated progress for this investigational therapy across all of our clinical programs.”
